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Human malignant glioma cells are characterized by local
invasion. In the present study, we investigated the role of
osteopontin (OPN) in the invasiveness of human glioma
cells isolated from grade IV tumors. We found that the
expression levels of OPN in these cell lines paralleled
matrix metalloproteinase-2 (MMP-2) expression and
cell invasiveness potential. When U87MG glioma cells
(with a high-OPN expression level) were stably trans-
formed with speciﬁc small hairpin RNA to knock
down OPN expression, MMP-2 secretion, cell invasive-
ness, and tumor growth in implanted brains were dra-
matically reduced. Conversely, forced expression of
OPN in GBM-SKH glioma cells (which expressed
OPN at a low level) increased MMP-2 secretion,
enhanced cell invasiveness, and increased tumor
growth in a rodent xenograft model. Expression of
OPN wasassociated with increased expression of vimen-
tin and decreased expression of glial ﬁbrillary acidic
protein. Treatment of glioma cells with 5-aza-20-deoxy-
cytidine (5-aza-dC) suppressed OPN expression in a
concentration-dependent manner. Suppression of OPN
expression by 5-aza-dC was associated with reductions
in MMP-2 secretion, vimentin expression, cell invasion,
intravasation, and tumor growth. These data suggest
that OPN may play important roles in regulating cell
invasion in glioma cells and that 5-aza-dC may serve
as a therapeutic agent for human gliomas.
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H
uman malignant gliomacells are characterized by
uncontrolled growth and rapid invasion of adja-
cent tissues. The standard treatment regimen
includes surgical debulking, radiation therapy, and cyto-
toxic chemotherapy using temozolomide. However, the
prognosis for gliomas remains poor with only 5% of
patients with a 5-year survival rate despite maximal
therapy.
1–3 Because current therapies fail to control
gliomas from invading contiguous normal brain tissues,
recent drug developments have focused on controlling
the invasive capability of gliomas. Malignant glioma
cells express certain known proteinases such as matrix
metalloproteinases (MMPs), which have been implicated
as important factors in regulating cell invasiveness and
angiogenesis in gliomas.
4 MMPs constitute a family of
enzymes with 25 members and 3 pseudo-MMPs, which
are extracellular endopeptidases requiring metal ions for
their enzymatic activity. Among the MMPs, attention
has focused on gelatinases (MMP-2 and MMP-9) in
human gliomas. A high level of MMP-2 expression was
observed in the higher-grade gliomas, which correlated
well with the malignant potential of human gliomas.
5
Osteopontin (OPN) is a non-collagenous, sialic acid-
rich, and glycosylated phosphoprotein secreted by the
osteoid matrix, which regulates osteoblast function
during bone formation.
5 In addition to bone remodeling,
OPN is also present in a variety of tissues and plays
important roles in inﬂammation, immune responses,
and biomineralization. OPN mediates cell adhesion,
migration, and invasion in a wide range of tumor
cells.
6–9 OPN is predominantly observed in the micro-
vasculature of glioblastomas and is implicated as an
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10 OPN is one of the
hypoxia-related genes, induced by hypoxia in vitro and
in vivo.
11 A suppression subtractive hybridization
study revealed that OPN plays crucial roles in brain
invasion.
12 OPN expression is implicated in the malig-
nancies of human malignant gliomas and is the most
up-regulated gene in the N-ethyl-nitrosourea-induced
glioma model in rats.
13–16 OPN is shown to regulate
MMP-2 expression and cell invasiveness in melanoma
cells.
17,18 Knockdown of OPN mRNA by small interfer-
ing RNA signiﬁcantly attenuates tumor cell motility and
invasiveness in CT26 colon cancer cells.
19
Vimentin is an intermediate ﬁlament protein, which is
up-regulated in highly inﬁltrative gliomas with poor prog-
nosis. Increased expression of vimentin is linked to malig-
nant tumor progression in melanomas and a variety of
cancers.
20–23 Vimentin is up-regulated in progressive
malignant gliomas under temozolomide treatment or
combined radiotherapy and chemotherapy and is postu-
lated to be a marker of a higher invasive phenotype.
24,25
In addition tovimentin expression, malignant progression
of neoplastic astrocytes is accompanied by a decrease in
glial ﬁbrillary acidic protein (GFAP) expression. GFAP
is an intermediate ﬁlament protein that is largely speciﬁc
for astrocytes and is among the best markers of astrocytic
differentiation.
26 GFAP is expressed in pilocytic astrocy-
toma and has been considered a marker that accurately
distinguishes pilocytic astrocytoma from glioblastoma.
12
In the present study, we investigated the roles of OPN
in MMP-2 production, cell invasiveness, and the
expressions of vimentin and GFAP in human glioma
cells, and we demonstrate that OPN plays an important
role in glioma cell invasion by enhancing MMP-2
secretion and vimentin expression in glioma cells.
5-Aza-20-deoxycytidine (5-aza-dC) is an anticancer drug,
currently used in the therapy of acute myeloid leukemia
and other myelodysplastic syndromes.
27,28 5-Aza-dC
also inhibits human medulloblastoma cell proliferation
and induces tumor cell apoptosis in glioma cells.
29,30 In
this report, we provide evidence that 5-aza-dC may regu-
late MMP-2 and vimentin expression through OPN
expression in human glioma cells. We demonstrated that
intraperitoneal administration of 5-aza-dC signiﬁcantly
reduced the tumor size in mice with intracranially
implanted tumors. These data suggest that 5-aza-dC
may beused as atherapeutic agent for gliomas by reducing
cell invasiveness through suppression of OPN expression.
Materials and Methods
Materials
Dulbecco’s modiﬁed Eagle’s medium (DMEM), fetal calf
serum(FCS),glutamine,gentamycin,penicillin,andstrep-
tomycin were purchased from Life Technologies
(Gaithersburg, Maryland). Antibody speciﬁc for MMP-2
was purchased from Sigma-Aldrich Chemical (St Louis,
Missouri). Anti-OPN and anti-a-tubulin antibodies were
purchased from Santa Cruz Biotechnology (Santa Cruz,
California). Horse-radish peroxidase (HRP)-conjugated
anti-rabbit IgG antibody was purchased from Bio-Rad
(Hercules, California). The RNAsin ribonuclease inhibi-
torandMoloney murineleukemiavirusreversetranscrip-
tase (RT) were purchased from Promega (Madison,
Wisconsin). Protease inhibitor cocktail tablets were pur-
chased from Boehringer Mannheim (Mannheim,
Germany). Human U87MG cells (American Type
Culture Collection no. HTB-14) were purchased from
the Institute of Food Sciences (Hsinchu, Taiwan).
GBM-SKH cells were isolated from a grade IV human
glioma by C.-C.L. of Shin Kong Memorial Hospital
(Taipei, Taiwan). GBM8401 cells were isolated from a
grade IV human glioma by H.-I.M. of Tri-services
General Hospital (Taipei, Taiwan).
Culture of Human Glioma Cells and Preparation
of Cell Lysates
U87MG cells and cell lines derived from human glioma
biopsies were cultured in DMEM supplemented with
13.1 mM NaHCO3, 13 mM glucose, 2 mM glutamine,
10% heat-inactivated FCS, and penicillin (100 U/mL)/
streptomycin (100 mg/mL). Cultures were maintained
in a humidiﬁed incubator with 5% CO2 at 378C. After
reaching conﬂuence, cells were treated with various con-
centrations of 5-aza-dC and incubated in a humidiﬁed
incubator at 378C for the indicated time-intervals. At
the end of incubation, cells were lysed by adding lysis
buffer containing 10 mM Tris–HCl (pH 7.5), 1 mM
EGTA, 1 mM MgCl2, 1 mM sodium orthovanadate,
1 mM DTT, 0.1% mercaptoethanol, 0.5% Triton
X-100, and protease inhibitor cocktails, then stored at
2708C for further determinations.
Sodium Dodecyl Sulfate Polyacrylamide Gel
Electrophoresis and Western Blotting
Proteins were separated by sodium dodecyl sulfate poly-
acrylamide gel electrophoresis. After electrophoresis,
proteins on the gel were electrotransferred onto a polyvi-
nyldiﬂuoride (PVDF) membrane. After transfer, the
PVDF membrane was washed once with PBS and twice
with PBS plus 0.1% Tween 20 (PBST). The PVDF mem-
brane was then blocked with blocking solution contain-
ing 5% non-fat dry milk in PBST for 1 hour at room
temperature. The PVDF membrane was blotted with
primary antibodies in the blocking buffer, and then
washed again in PBST. The PVDF membrane was incu-
bated with peroxidase-linked anti-mouse immunoglio-
bin G antibodies for 1 hour and then developed by an
enhanced chemiluminescence plus detection kit
(Amersham Life Sciences, Piscataway, New Jersey),
and the relative photographic density was quantitated
by scanning the photographic negatives on a gel analysis
system (BioSpectrumAC Imaging System Vision Work
LS software, UVP Inc., Upland, California).
Gelatin Zymography
Gelatinolytic zymography was used to detect the
secretion of MMP-2 in the culture media. Brieﬂy, the
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onto 10% SDS–PAGE co-polymerized with 0.1%
gelatin and subjected to electrophoresis at 100 V for
1.5 hours. In order to remove the SDS, the gel was
washed twice with a 2.5% Triton X-100 solution for
30 minutes each, rinsed with incubation buffer
(0.05 M Tris–HCl buffer [pH 8.0], 5 mM CaCl2, and
5 mMZ n C l 2), and incubated at 378C overnight. The
gel was then stained with a solution of 0.25%
Coomassie blue R250, 40% methanol, and 10% acetic
acid for 2 hours at room temperature and destained
with 40% methanol and 10% acetic acid until the lysis
bands became clear. Gelatinase activities in the media
were detected as unstained gelatin-degraded zones on
the gel. The MMP-2-relative photographic density was
quantitated by scanning the photographic negatives on
a gel analysis system (BioSpectrumAC Imaging System
Vision with LS software, UVP Inc.).
Transfection of Plasmids
For OPN knockdown, U87MG cells were seeded at 5  
10
5 cells per 6-cm plateand allowed to adhere overnight.
The next day, a vector control (plKo) and OPN-speciﬁc
small hairpin RNA plasmid (shOPN) (oligo sequence:
CCGGCCACAAGCAGTCCAGATTATACTCGAGT-
ATAATCTGGACTGCTTGTGGTTTTT) were trans-
fected into cells using Lipofectamine 2000 (Invitrogen).
After 24 hours, transfected cells were split equally into
6-cm plates and allowed to adhere overnight. For OPN
overexpression, GBM-SKH cells were seeded at 5  
10
5 cells in a 6-cm plate. Next day, pcDNA3.1/OPN
(accession no. NM_000582) or the control pcDNA3.1
vector was transfected. After 24 hours, the medium
was changed to select G418-resistant clones.
In Vitro Matrigel Invasion Assay (Boyden Chamber)
In vitro invasion of glioma cells was measured using
Matrigel-coated transwell inserts (BD Biosciences,
Mansﬁeld, Massachusetts). Brieﬂy, glioma cells (2  
10
5) pretreated under the indicated conditions were sus-
pended in serum-free DMEM in the upper wells and
allowed to transmigrate through the membrane inserts
toward the lower wellsthat were ﬁlled with DMEM con-
taining 10% FCS. At the end of incubation, non-
invading cells on the upper side of the membrane were
gently removed using a cotton-tipped swab. Cells
which had migrated to the lower side of the membranes
were ﬁxed, stained with toluidine blue solution
(Sigma-Aldrich), and counted.
Total RNA Isolation and RT-Polymerase Chain
Reaction
Total RNA was extracted from cultured glioma cells
using TRIzol reagent (Invitrogen). Two micrograms of
total RNA were used for cDNA synthesis by RT. The
reaction was carried out in a 20-mL reaction mixture
containing 1 mg of total cellular RNA, 1  buffer
(50 mM Tris [pH 8.3], 61.5 mM KCl, and 3 mM
MgCl2); 1 mM each of dATP, dTTP, dGTP, and
dCTP, 20 pmol of a random hexamer, and 200 U of
RT (Superscript II Rnase H
2, Gibco BRL, Carlsbad,
California) at 258C for 10 minutes and then at 428C
for 50 minutes. The reaction was stopped by incubating
the reaction mixture at 708C for 15 minutes. Primers for
MMP-2 (forward: 50-GAGTTGGCAGTGCAATACC
T-30; reverse: 50-GCCGTCCTTCTCAAAGTTGT-30),
OPN (forward: 50-GAAAGCGAGGAG TTGAATGG
-30; reverse: 50-TTCCATGAAGCCACAAACTA-30), and
glyceraldehyde-3-phosphate dehydrogenase (forward:
50-GCCAAAAGGGTCATCATCTCTG-30; reverse: 50-C
ATGCCAGTGAG CTTCCCGT-30) were derived from
human cDNA sequences, and polymerase chain reaction
(PCR) conditions were optimized so that the gene pro-
ducts were in the exponential phase of ampliﬁcation
(948C for 2 minutes, then for 30 cycles at 948Cf o r
30 s, 558Cf o r1m i n u t e s ,a n d7 2 8C for 1 minute, fol-
lowed by a ﬁnal elongation for 7 minutes at 728C).
PCR products were resolved on 1.5%–2% agarose gels
containing 1 mg/mL ethidium bromide.
In Vivo Intravasation Assay
The chorioallantoic membrane (CAM) intravasation
assay was carried out according to Kim et al.
31 with
few modiﬁcations. Chicken embryos at 10 days of ges-
tation were incubated in a rotary incubator at 388C
with 60% humidity. A small hole was drilled into the
top of the egg above the area of greatest vasculature,
causing the CAM to detach from the shell membrane.
Human glioma cells (10
5), in a volume of 50 mL of com-
plete corresponding enzymatic-free cell culture media,
were inoculated onto the dropped CAM with a pipette
tip (5 eggs for each tumor type). The holes were sealed
with tape, and the eggs were returned to the incubator.
Ten days after inoculation (day 14), the eggs were care-
fully opened. The CAMs lining the cavity of the eggshell
were removed, snap-frozen, and used for the extraction
of genomic DNA. The frozen CAMs were crushed to a
powder, suspended in digestion buffer (100 mM NaCl,
10 mM Tris–Cl [pH 8.0], 25 mM EDTA, 0.5% SDS,
and 0.1 mg/mL proteinase K), and incubated at 508C
for 18 hours. Genomic DNA in the sample was extracted
using the Sigma genomic isolation kit (Sigma Chemical).
Intravasation of human glioma cells was demonstrated
by the presence of the human Alu sequence in the
CAM. Human Alu sequence was analyzed by a
PCR-based assay, which produced an Alu band of
224 bp.
31 The PCR products were resolved on a 2%
agarose gel containing 1 mg/mL ethidium bromide.
The primers for the human Alu sequence were
forward: 50-ACGCCTGTAATCCCAGCACTT-30 and
reverse: 50-TCGCCCAGGCTGGAGTGCA-30.
Cell Viability Assays
For the dye exclusion assay, cells were seeded at 2.5  
10
4 per well in 24-well plates. Media were removed,
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with trypsin. Cells were then washed, and resuspended
in 0.4% trypan blue, and live cells were counted on
a hemocytometer. Cell viability was evaluated using
an 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenytetrazolium
bromide (MTT) assay. Glioma cells grown on the
150-mm plates were washed twice with PBS and resus-
pended into DMEM. The suspended cells were plated
on 24-well plates (2   10
5 cells/well) and treated with
the indicated reagent(s) for 24 hours. MTT was added
to the medium (1 mg/mL), and cells were incubated at
378C for 2 hours. Then dimethylsulfoxide (100 mL)
was applied to the medium to dissolve the formazan
crystals derived from mitochondrial cleavage of the tet-
razolium ring of MTT. The absorbency at 570 nm in
each well was measured on a micro-enzyme-linked
immunosorbent assay plate reader. None of the reagents
used in this study interfered with the MTT values.
In Vivo Intracranial Xenograft Studies
Cells were freshly prepared and adjusted to 1  
10
5 cells/mL before implantation. An intracranial xeno-
graft was performed according to the Institutional
Animal Care and Use Committee-approved protocols.
Brieﬂy, nude mice were anesthetized and placed in a
stereotactic frame, and the skull was exposed by
incision. A hole was made 3 mm to the right of the
bregma, and cells (5 mL) were injected using a 10-mL
Hamilton syringe with a 26S-gage needle mounted in a
stereotactic holder. The syringe was lowered to a depth
of 3.5 mm and then raised to a depth of 2.5 mm. The
glioma cells were injected at a rate of 0.5 mL/10 s.
After intracranial implantation, a 5-minute waiting
period was observed before slowly withdrawing the
syringe to prevent any reﬂux. The skull was then
cleaned, the hole was sealed with bone wax, and the
incision was sutured. Tumors were allowed to grow,
and animals were sacriﬁced on day 21, or when the
animals developed signs of neurological deﬁcits.
32, 33
Mice were perfused, and the brains were extracted and
post-ﬁxed in 4% paraformaldehyde overnight and
then embedded in parafﬁn for further analysis.
Formalin-ﬁxed, parafﬁn-embedded tissue sections were
dewaxed in xylene for 10 minutes, rehydrated in
alcohol solution, and stained with hematoxylin and
eosin (H&E). The size of brain tumors was microscopi-
cally determined as described by Ma et al.
32, 33 Brieﬂy,
all tumors were sectioned through their largest diameter,
and representative sections were used for quantitative
analyses. The mean values of the sections from three
independent experiments in each group were used for
the quantitative analyses of tumor sizes.
Administration of 5-aza-dC and
Immunohistochemistry
Nude mice implanted intracranially with 5   10
5
human glioma cells were administered 5-aza-dC
(3.75 mg/kg) or PBS at 48-hour intervals by an
intraperitoneal injection. Mice were sacriﬁced by
cardiac puncture 21 days after implantation. Parafﬁn
sections were prepared for immunohistochemical stain-
ing for OPN, GFAP, and vimentin. Brieﬂy, 4–
6-mm-thick sections were cut using a microtome and
applied to PLL-coated slides. Sections were deparafﬁ-
nized, rehydrated, and placed in 5% hydrogen peroxide
in absolute alcohol for 10 minutes to block the endogen-
ous peroxidase activity. To unmask the antigen by heat
treatment, slides were placed in a container, covered
with 10 mM sodium citrate buffer (pH 6), and heated
to 958C for 5 minutes. The slides were tapped off with
fresh buffer and heated at 958C for 5 minutes and then
allowed to cool in buffer for 20 minutes. Slides were
washed in deionized water 3 times, for 2 minutes each,
on a stirring plate. All subsequent steps were carried
out at room temperature in a humidiﬁed chamber.
Tissue sections were not allowed to dry out at any
time during the procedure. The primary antibody was
diluted (1:50) in a sufﬁcient volume to cover the tissue
and incubated for 2 hours. Slides were rinsed with PBS
and then washed in PBS twice for 2 minutes each on a
stirring plate. Sections were incubated for 30 minutes
in a biotinylated secondary antibody at a dilution of
1:200. Slides were rinsed with PBS and then washed
with PBS twice for 2 minutes each on stir plate. Tissue
sections were then incubated with a HRP-streptavidin
complex (Dako) for 30 minutes before being washed
again with PBS. The immunostaining was visualized by
development in diaminobenzidine before being counter-
stained with Mayer’s H&E stain.
Statistical Analysis
Results are expressed as the mean+standard error of
the mean (SEM) from the number of independent exper-
iments performed. One-way analysis of variance
(ANOVA) was used to assess the difference of means
among groups, and Student’s two-tailed t-test was used
to determine the difference of means between any two
groups. A P value of ,.05 was taken as statistically
signiﬁcant.
Results
OPN Expression Correlates to Increased Invasiveness
in Cell Lines Derived from Human Gliomas
Invasive growth of gliomas may be directly related to
histologic malignancy, but occurs to some extent irre-
spective of tumor grade. We ﬁrst compared the capabili-
ties of invasiveness and proliferation rates of U87MG
cells and two other cell lines derived from human
grade IV gliomas (GBM-SKH and GBM8401). As
shown in Fig. 1A and B, cell invasiveness and prolifer-
ation rates were higher in U87MG and GBM8401 cells
andlower inGBM-SKHcells. Toconﬁrm the differential
cell invasiveness of these glioma cells in vivo, an intrava-
sation assay based on the CAM model using chicken
embryos was carried out. Although GBM-SKH cells
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NEURO-ONCOLOGY † JANUARY 2010 61Fig. 1. Cell lines derived from human gliomas exhibit different growth rates, invasiveness, and intravasation. (A) For the in vitro invasion
assay, equal numbers of glioma cells were seeded in the upper part of a transwell coated with Matrigel. After 24 hours, cells on the
bottom side of ﬁlter were ﬁxed, stained, and counted. Data represent the mean+SE of three independent experiments. (B) Viable cell
numbers were counted at 24, 48, and 72 hours. Data represent the mean+SE of three independent experiments. (C) A chicken embryo
CAM model was used for the in vivo intravasation assay. Intravasation was demonstrated by ampliﬁcation of the human Alu sequence
from DNA extracted from the isolated CAMs. P, positive control; N, negative control. (D) Medium was collected and MMP-2
gelatinolytic activities were analyzed by zymography. In the lower panel, the MMP-2 activity was quantitated by scanning the
photographic negatives on a gel analysis system. (E) MMP-2, OPN, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA
expressions were analyzed by RT–PCR. (F) Cell lysates were harvested and immunoblotted with antibodies speciﬁc for MMP-2, OPN,
and a-tubulin. The upper panels of (E) and (F) are representative data, these experiments were repeated, and the intensities of bands
were quantitated and expressed as ratios to equal loading controls. Results shown in the lower panels are the mean+SE of three
independent experiments. *P , .05, compared with U87MG.
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U87MG and GBM8401 cells exhibited the ability to
intravasate (Fig. 1C). Because MMP-2 secretion has
been linked to cell invasiveness, we next examined the
gelatinolytic activity in cultured media of these cells.
Figure 1D shows that the MMP-2 gelatinolytic activities
secreted by U87MG and GBM8401 were much higher
than those of GBM-SKH cells. OPN has been shown
to induce MMP-2 production and activation in many
cancer cells and has been correlated with malignancies
of gliomas.
6–8 Next, we examined the OPN mRNA
and protein expressions in glioma cells. The mRNA
expression levels of OPN and MMP-2 were higher in
U87MG and GBM8401 cells compared with
GBM-SKH cells (Fig. 1E). Similar protein expression
patterns of MMP-2 and OPN were found in cell
lysates prepared from these cells (Fig. 1F).
OPN Knockdown Suppressed Cell Invasiveness and
Tumor Growth in U87MG Glioma Cells
To further examine the role of OPN in cell invasiveness
and tumor growth, shRNA speciﬁc for OPN was used to
knock down OPN expression in the more invasive
U87MG cells (that expressed a higher OPN level).
Knockdown of OPN expression was demonstrated by
suppression of OPN mRNA and protein expression in
U87MG cells (Fig. 2A and B). The gelatinolytic activity
secreted by U87MG cells was also lowered in
OPN-knockdown cells (Fig. 2C). We next determined
whether knockdown of OPN altered Matrigel invasion
by U87MG cells. As shown in Fig. 2D, knockdown of
OPN dramatically reduced cell invasiveness in U87MG
cells. To evaluate whether OPN gene expression affects
tumor cell proliferation, we examined the number of
viable cells using the trypan blue exclusion assay. As
shown in Fig. 2E, knockdown of OPN reduced the
number of viable cells in U87MG cells. To explore
further, we employed an intracerebral xenograft mouse
model to investigate tumor growth in nude mice.
U87MG cells were either stably transfected with OPN
shRNA or a control vector before cell implantation.
On day 21 after tumor inoculation, tumor volumes
were evaluated in half of the animals. Tumor size was
smaller in animals implanted with OPN-knockdown
U87MG cells compared with those implanted with
control U87MG cells (Fig. 2F).
Increased Expression of OPN-Enhanced Invasiveness
by GBM Cells
To further conﬁrm the role of OPN in mediating cell
invasiveness and tumor growth, OPN was overexpressed
in the less-invasive GBM-SKH glioma cells, and
Matrigel invasion and tumor growth in nude mice
were examined. As shown in Fig. 3A and B, transfection
of an OPN-bearing plasmid increased OPN mRNA and
protein levels in GBM-SKH cells. Overexpression of
OPN was associated with increased MMP-2 mRNA
and protein expressions in the cells (Fig. 3A and B)
and gelatinolytic activity in the media of GBM-SKH cul-
tures (Fig. 3C). Overexpression of OPN in GBM-SKH
cells also promoted cell invasiveness (Fig. 3D) and the
cell proliferationrate in vitro(Fig. 3E). Tofurther under-
stand the roles of OPN in glioma tumor growth, nude
mice were implanted intracranially with GBM-SKH
cells bearing an empty vector or GBM-SKH cells that
overexpressed OPN. Tumor size was signiﬁcantly
increased in animals implanted with OPN overexpres-
sing GBM-SKH cells compared with those implanted
with control GBM-SKH cells (Fig. 3F). Figure 4 shows
a high magniﬁcation photo of H&E stain of brain
tissue sections. Invasion nests in surrounding brain
tissue were noted in mouse brains implanted with the
highly invasive U87MG cells but not those implanted
with OPN-knockdown U87MG cells. Conversely, inva-
sion nests were noted in OPN-overexpressing
GBM-SKH cells, but not in brain tissues grafted with
the low-invasive GBM-SKH cells. To demonstrate that
tumor invasiveness was associated with OPN overex-
pression, immunohistochemical staining was performed.
The microphotograph shows cytoplasmic staining of
OPN in the main tumor mass and invasion nests of
tumor cells in rat brain tissues (Fig. 4, right panels).
These results suggestedthatOPN enhanced cell invasive-
ness in vivo.
OPN Regulates Vimentin and GFAP Expressions
in Glioma Cells
Increased expression of vimentinand the progressiveloss
ofGFAPareassociatedwithahighdegreeofinvasiveness
and tumor growth in human gliomas.
26 To explore the
possibility that OPN may contribute to increased vimen-
tinanddecreasedGFAPexpressions,vimentinandGFAP
protein levels were examined in cells expressing different
OPNlevels.AsshowninFig.5A,U87MGcellsexpressed
low GFAP and high vimentin protein levels. Knockdown
of OPN resulted in increased GFAP expression and
decreased vimentin expression in U87MG cells. On the
other hand, forced expression of OPN in GBM cells
(which expressed a low OPN level) slightly decreased
GFAP protein expression and increased the vimentin
protein level (Fig. 5A, left panel). The in vitro data
could be replicated in the intracranial xenograft mice
model. As shown in Fig. 5B, implantation of
OPN-knockdown U87MG/shOPN cells into mouse
brains resulted in increased GFAP expression and
decreased vimentin expression in brain sections.
Consistently, overexpression of OPN in GBM cells led
to a slight decrease in GFAP and an increase in vimentin
immunoreactivity in brain sections. Thus, OPN may
play a role in tumor progression of gliomas.
5-Aza-dC Reduces Glioma Cell Invasiveness and
Growth In Vitro and In Vivo via OPN Expression
5-Aza-dC has been used to treat acute myeloid leukemia
and other myelodysplastic syndromes and has also been
shown to reduce human trophoblastic cell migration and
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NEURO-ONCOLOGY † JANUARY 2010 63Fig. 2. U87MG cells were either stably transfected with an OPN shRNA plasmid or with a plKo shRNA vector as mock control. (A) MMP-2,
OPN, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA expressions were analyzed by RT–PCR. (B) Cell lysates were
harvested and immunoblotted with antibodies speciﬁc for OPN, MMP-2, and a-tubulin. These experiments were repeated, and the
intensities of bands were quantitated and expressed as ratios to mock control cells. Results shown in the lower panel of (A) and (B) are
the mean+SE of three independent experiments. (C) Media were collected for the zymographic assay of MMP-2 activity. In the lower
panel, MMP-2 activity was quantitated by scanning the photographic negatives on a gel analysis system. (D) For the in vitro invasion
assay, cells were seeded in equal amounts cells in the upper part of transwell chamber separated by a Matrigel-coated membrane.
Migrated cells on the bottom of the membrane were counted. Data represent the mean+SE of three independent experiments. (E)
Cells were seeded in culture plates in DMEM media supplemented with 10% heat-inactivated FCS. Viable cell numbers were counted.
Data represent the mean+SE of three independent experiments. (F) Histopathological characteristics (H&E) and tumor volumes of
animals implanted with U87/plKo or U87MG/shOPN. Tumor sizes were measured through their largest diameter (upper panel), and the
lower panel shows the mean+SE of three independent experiments. *P , .05, compared with U87/plKo.
Jan et al.: OPN regulates glioma cell invasion
64 NEURO-ONCOLOGY † JANUARY 2010Fig. 3. GBM-SKH cells were stably expressed without or with the control vector (pcDNA3.1) or with wild-type OPN (pDNA3.1/OPN). (A)
MMP-2, OPN, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA expression were analyzed by RT–PCR. (B) Cell lysates
were harvested and immunoblotted with antibodies speciﬁc for OPN, MMP-2, and a-tubulin. These experiments were repeated, and the
intensities of bands were quantitated and expressed as ratios to mock control cells. Results shown in the lower panel of (A) and (B) are
the mean+SE of three independent experiments. (C) Media were then collected for the zymographic assay of MMP-2 activity. In the
lower panel, MMP-2 activity was quantitated by scanning the photographic negatives on a gel analysis system. (D) For the in vitro
invasion assay, cells were seeded in equal amounts of experimental cells in the upper part of a transwell chamber separated by a
Matrigel-coated membrane. Data represent the mean+SE of three independent experiments. (E) Cells were seeded in culture plates in
DMEM media supplemented with 10% heat-inactivated FCS. Viable cell numbers were counted at 24, 48, and 72 hours. Data represent
the mean+SE of three independent experiments. (F) Histopathological characteristics (H&E) and tumor volumes of animals implanted
with GBM/pcDNA or GBM/OPN were evaluated. Tumor sizes were measured through their largest diameter (upper panel), and the
lower panel shows the mean+SE of three independent experiments. *P , .05, compared with pDNA3.1/OPN.
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34 Because 5-aza-dC can cross the blood-brain
barrier effectively,
35 we examined whether 5-aza-dC
could be used in glioma therapy. We ﬁrst tested
whether 5-aza-dC suppressed MMP-2 secretion in
human glioma cells. Treatment of U87MG cells with
5-aza-dC for 24 hours did not alter the viability of
U87MG cells as demonstrated by the MTT assay
(Fig. 6B). However, incubation of glioma cells with
5-aza-dC (0–10 mM) reduced the MMP-2 gelatinolytic
activity in the culture media of human glioma cells
(Fig. 6A). Western blot analysis revealed that treatment
with 5-aza-dC decreased OPN protein expression,
which paralleled the decreased MMP-2 protein levels
in U87MG cells. 5-Aza-dC has been demonstrated to
induce differentiation in human hematopoietic progeni-
tor cells.
4 We demonstrated that 5-aza-dC induced
GFAP expression and decreased vimentin expression in
U87MG cells (Fig. 6C). We next examined the effects
of 5-aza-dC on cell invasiveness and intravasation by a
Matrigel invasion assay and the chicken CAM model.
The in vitro invasiveness through Matrigel in U87MG
cells was reduced in cells treated with 5-aza-dC
(Fig. 6D). Furthermore, although control U87MG cells
intravasated well into the vasculature of CAM,
5-aza-dC-treated cells failed to intravasate after 4 days
of incubation (Fig. 6E). Treatment with 5-aza-dC also
reduced the cell proliferation rate in human glioma
cells (Fig. 6F). To evaluate whether 5-aza-dC can be
Fig. 4. U87MG cells were either stably transfected with OPN shRNA or with control shRNA; GBM-SKH cells were stably expressed with a
control vector (pcDNA3.1) or with wild-type OPN (pDNA3.1/OPN). These cells were implanted into nude mice intracranially. Twenty-one
days after implantation, mice were sacriﬁced and H&E staining and immunohistochemical analyses of OPN were performed. The arrows
show the invasion of glioblastoma cells into surrounding brain tissue (left panels) and cytoplasmic OPN expression in invasive cells (right
panels).
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whether an intraperitoneal injection of 5-aza-dC
affected tumor growth in an intracranial xenograft
model. U87MG cells (1   10
6) were transplanted into
mousebrains.Afterimplantation,micewereadministered
5-aza-dC (3.75 mg/kg) or PBS at48-hour intervals byan
intraperitoneal injection. Mice were sacriﬁced by cardiac
puncture at 21 days, and tumor volumes were evaluated
microscopically in these animals. As shown in Fig. 6G,
tumor size was signiﬁcantly reduced in animals adminis-
tered 5-aza-dC. These data suggest that 5-aza-dC can be
used for glioma therapy.
Fig. 5. OPN regulates vimentin and GFAP protein levels in glioma cells. (A) U87MG cells were stably transfected either with OPN shRNA or
with control shRNA (left panel); GBM-SKH cells were stably expressed with a control vector (pcDNA3.1) or with wild-type OPN (pDNA3.1/
OPN) (right panel); Cell lysates were harvested and immunoblotted with antibodies speciﬁc for GFAP and vimentin. These experiments were
repeated, and the intensities of bands were quantitated and expressed as ratios to mock control cells. Results in the lower panel of (A) are the
mean+SE of three independent experiments. *P , .05, compared with U87/plKo. (B) H&E staining, immunohistochemical analyses of
GFAP, and vimentin in U87/plKo, U87/shOPN, GBM/pcDNA, and GBM/OPN. Mice were sacriﬁced and brain tissue extracted 21 days
after implantation. Positive staining is indicated by arrows.
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assay for MMP-2 activity. In the lower panel, effects of 5-aza-dC on MMP-2 secretion in various cells were quantitated by scanning the
photographic negatives on a gel analysis system and are expressed as a percent of basal level for each cell line. (B) Cell viability was
analyzed by the MTT assay after incubation of U87MG cells with 5-aza-dC for 24 hours. (C) Cell lysates were harvested and
immunoblotted with antibodies speciﬁc for OPN, MMP-2, GFAP, vimentin, and a-tubulin. (D) For the in vitro invasion assay, equal
numbers of glioma cells were seeded in the upper part of a transwell coated with Matrigel in the presence of different concentrations of
5-aza-dC. After 24 hours, cells on the bottom side of the ﬁlter were ﬁxed, stained, and counted. Data represent the mean+SE of three
independent experiments. (E) An intravasation assay was carried out. PCR ampliﬁcation for Alu sequence is shown. P, positive control;
N, negative control. (F) A trypan blue exclusion assay was carried out after treating cells with different concentrations of 5-aza-dC in
5% FBS medium for different time periods. Data represent the mean+SE of three independent experiments. (G) Measurement of
implanted tumor sizes in mice without or with 5-aza-dC administration. Tumor sizes were measured through their largest diameter
(upper panel), and the lower panel shows the mean+SE of three independent experiments. *P , .05, compared with basal level.
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The prognosis for patients with a glioma remains dismal
because current therapies fail to control gliomas from
invading normal contiguous brain tissues. In the present
study,weexaminedthecapabilitiesofinvasionandintra-
vasation in cells isolated from two WHO grade IV glio-
blastoma multiforme samples and in U87MG cells. We
found that cell invasiveness signiﬁcantly differed among
these human glioma cells. We further demonstrated that
these differences may be attributed to their expression
levels of OPN. This premise is supported by data where
the knockdown of OPN in glioma cells decreased cell
invasiveness and proliferation in vitro and in vivo, and
the overexpression of OPN increased cell invasiveness
and tumor growth. Additionally, we demonstrated that
treatment with 5-aza-dC reduced OPN expression in
U87MG cells, which resulted in a reduction in tumor
size in intracranially implanted nude mice. Our results
support the notion that OPN may serve as a therapeutic
target and that 5-aza-dC can be used in the treatment of
human malignant gliomas.
The expression of OPN has been correlated with
increased tumor grade and migratory capacity of tumor
cells.
13,36 We demonstrated that glioma cell lines isolated
from grade IV gliomas exhibited different capabilities of
tumor invasion and expressed different levels of OPN
and MMP-2. We presented evidence that alteration of
OPNexpressionlevelsresultedinchangesincell invasive-
ness and MMP-2 release. We showed that knockdown of
OPNexpressionin highlyinvasive U87MGcellsresultsin
a reduction of MMP-2 expression, a decrease in cell inva-
sion, and delayed tumor growth in mice. Consistently,
overexpression of OPN in low-invasive GBM glioma
cells leads to increases in MMP-2 secretion, cell invasive-
ness through Matrigel in vitro, and tumor growth in vivo.
These results are consistent with a previous report that
showed that suppression of MMP-2 gene expression
may result in decreased invasiveness in malignant
gliomas.
37 We extended those ﬁndings by showing that
OPN is intimately linked to MMP-2 secretion, cell inva-
siveness, and in vivo tumor growth in malignant gliomas.
The expression level of GFAP is associated with glial
cell differentiation and can be considered as a diagnostic
marker for the differentiation of gliomas.
26 Vimentin is
an intermediate ﬁlament abundantly produced in the
developing central nervous system. Expression of vimen-
tin enhances motility and the invasive potential of astro-
cytoma cell lines and is a marker for poorly
differentiated astroglial cells.
24 In the present study, we
showed that highly invasive U87MG cells express more
vimentin and less GFAP. Knockdown of OPN resulted
in a reduction in cell invasiveness, a decrease in vimentin
expression, and an increase in the GFAP protein level.
These data support the notion that OPN may regulate
cell invasiveness through the expressions of vimentin
and GFAP. Consistently, 5-aza-dC-reduced OPN
expression, which was associated with increased GFAP
and decreased vimentin expression in U87MG cells.
Given that OPN may regulate MMP-2 expression and
vimentin expressions, OPN can be considered a candi-
date target for human glioma therapy.
5-Aza-dC (Decitabine) has now been successfully
advanced to clinical trials for the treatment of hemato-
poietic malignancies.
38 In the present study, we demon-
strated that treatment of cells with 5-aza-dC suppressed
MMP-2 secretion and U87MG cell invasiveness. Because
5-aza-dC isapotentinhibitorofDNA methyltransferase,
DNA hypomethylation may account for the suppression
of OPN expression in glioma cells. Indeed, 5-aza-dC sup-
pressesgeneexpressionsbyunmethylatingtheCpGsatthe
upstream-activating sequences.
39,40 However, it has also
been shown that 5-aza-dC may inhibit glioma invasive-
growth ability through a DNA methylation-independent
mechanism. The detailed mechanisms by which 5-aza-
dC suppresses OPN expression are currently not clear
and warrant further investigation.
In conclusion, our results suggest that OPN may play
an important role in regulating MMP-2 secretion and
tumorinvasion.Wedemonstratedthatanintraperitoneal
injection of 5-aza-dC may suppress OPN and MMP-2
expressions and tumor growth in a rodent model. On
the other hand, although temozolomide has proved to
be efﬁcacious in the treatment of human gliomas, the
expression of O
6-methylguanine-DNA methyltransfer-
ase has rendered glioma cells resistant to temozolomide
therapy. Given that 5-aza-dC may effectively suppress
tumor growth in vivo and exert extra-beneﬁcial effects
in temozolomide therapy, 5-aza-dC may be considered
a standard treatment regimen for glioma therapy.
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